Competition to heat up in domestic anti-hepatitis B drug market

Heated competition in the domestic anti-hepatitis B drug market, which has been dominated by BMS Korea’s Baraclude, is expected from next year because Yuhan Corp. and Boryung Pharm have been deploying aggressive marketing strategies for Gilead Sciences’ Viread from December.

Baraclude, a drug that was launched in 2007 here and now generates the largest revenue among prescription medicines, h...